What is the difference between full-spectrum and broad-spectrum cannabis extracts?

Full-spectrum extracts retain the complete cannabinoid and terpene profile of the source plant, including THC. Broad-spectrum extracts have undergone a processing step to remove or reduce THC to non-detectable levels while aiming to preserve other cannabinoids and terpenes. Neither term has a standardised pharmacopoeial definition, so third-party certificate of analysis documentation is the only reliable way to verify actual content.

Is a CBD isolate more or less bioavailable than a full-spectrum extract?

Bioavailability is primarily determined by the formulation and delivery method — whether oil-based, emulsified, encapsulated, and so on — rather than by the full-spectrum versus isolate distinction itself. Oral bioavailability of CBD is typically cited at 6–19% in published literature regardless of extract type, largely due to first-pass metabolism and CBD's high lipophilicity.

Is full-spectrum cannabis available over the counter in Australia?

No. Products containing THC above a prescribed threshold are Schedule 8 controlled drugs or Schedule 4 prescription-only medicines under Australia's Poisons Standard and require access via the TGA's Special Access Scheme or an Authorised Prescriber. Only low-dose CBD products (up to 150mg per pack, max 60mg/day) were down-scheduled to Schedule 3 (pharmacist-only) in 2021 — and those are typically isolate or broad-spectrum formulations with non-detectable THC.

What is the entourage effect and is it scientifically accepted?

The entourage effect is a hypothesis proposing that cannabinoids and terpenes act together to produce effects that no single compound could achieve alone. There is credible mechanistic evidence supporting the plausibility of this hypothesis — terpenes like beta-caryophyllene interact directly with CB2 receptors, for instance — but clinical evidence sufficient to draw firm population-level conclusions has not yet been established. It is an active area of research, not a settled finding.

Does 'broad-spectrum' mean there is definitely zero THC in a product?

Not necessarily. 'Broad-spectrum' describes an intent — to remove THC while retaining other plant compounds — but the term has no single regulated definition across the industry. Analytical verification via a certificate of analysis from an accredited third-party laboratory is the only way to confirm actual THC content in a specific product batch.

Full-Spectrum vs Broad-Spectrum vs Isolate

By Tom Whitfield · 11 May 2026 · 10 min read

Three labels, one very loaded question

Roughly 160 cannabinoids have been identified in Cannabis sativa to date. That number rarely appears in the consumer-facing conversation. Instead, the label says "full-spectrum" or "isolate" and leaves the reader to reverse-engineer the chemistry. The full-spectrum vs broad-spectrum vs isolate question is really a question about how much of that plant chemistry survives into a finished product, and the gap between the shelf and the literature is exactly why these terms are worth unpacking properly.

This article describes the chemistry and classification of three formulation categories. It does not recommend any product, dose, or formulation approach. It is general education, not advice about any person's circumstances.

A quick note on terminology before we start. "Spectrum" here is a marketing and descriptive word, not a regulatory one. It tells you roughly which families of compounds the manufacturer says are present. It does not tell you how much of each, in what form, or how consistently from one batch to the next. Keep that in mind through every section below.

What "full-spectrum" actually means at the chemistry level

A full-spectrum extract is, in principle, a representation of the whole plant profile: the major cannabinoids, the minor ones, and the volatile aromatic compounds called terpenes. The goal during extraction is to carry that chemical complexity through to the final product without stripping constituents away. The qualifier "in principle" matters, because every extraction method keeps some compounds better than others.

That means you'll find cannabidiol (CBD), yes, but also smaller concentrations of compounds like cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC), and, depending on the source plant, varying levels of tetrahydrocannabinol (THC). There may also be acidic precursor forms present, including THCA and CBDA, which haven't undergone the heat-driven decarboxylation step that converts them to their neutral counterparts. The distinction between acid and neutral forms is a common source of confusion on labels, and it is covered in more detail in cannabinoid acids vs neutral forms.

On the terpene side, you might expect to find compounds like myrcene, limonene, beta-caryophyllene, linalool, and alpha-pinene, among others. These aren't just aromatic molecules. They interact with various receptors in the body independently of the cannabinoid pathways, which is part of why researchers take them seriously rather than treating them as incidental. Because terpenes are so volatile, how gently a producer handles them matters a great deal, a topic explored in terpene preservation in extraction.

Where full-spectrum sits in Australian regulation

The regulatory picture matters here. In Australia, any full-spectrum extract derived from cannabis that contains THC above a prescribed threshold is a controlled substance under the Poisons Standard. Products containing THC are Schedule 8 controlled drugs or Schedule 4 prescription-only medicines depending on concentration and formulation, and access is strictly through the Therapeutic Goods Administration's Special Access Scheme or via an Authorised Prescriber. Full stop. There is no legal over-the-counter pathway for THC-containing products in Australia.

If those scheduling terms are unfamiliar, Schedule 4 vs Schedule 8 sets out how the two classes differ, and the Poisons Standard (SUSMP) explained covers how the schedules are built and maintained. The two access routes named above are described in understanding the Special Access Scheme and the Authorised Prescriber Scheme. For the regulator itself, see the Therapeutic Goods Administration (TGA) explained.

The practical point is simple. "Full-spectrum" describes chemistry, while the schedule describes legal status, and the second is driven by the actual contents of the final product rather than by the word on the front of the pack.

Full-spectrum vs broad-spectrum: the middle ground, and why it's complicated

A broad-spectrum extract is broadly (sorry) defined as a full-plant-profile extract from which THC has been selectively removed or reduced to non-detectable levels. The idea is to retain the minor cannabinoids and terpenes while eliminating the compound that triggers Schedule 8 classification.

Sounds clean in theory. In practice, the removal step, typically chromatographic separation, inevitably affects the broader profile to some degree. Chromatography works by moving a mixture through a medium so that different molecules travel at different speeds, and molecules with similar chemical behaviour can travel together. Some minor cannabinoids co-elute with THC during certain separation techniques, meaning they're partially or fully removed as well. The terpene fraction, being highly volatile, can also be diminished depending on processing temperatures.

So "broad-spectrum" doesn't have a single, standardised chemical definition across the industry; it's closer to a marketing category than a pharmacopoeial one. I'll be honest, that inconsistency bothers me more than it probably should. Two products with the same label can differ meaningfully in which minor compounds remain, and nothing on the front of the pack will tell you.

Manufacturers who want to substantiate a "broad-spectrum" claim need rigorous third-party certificate of analysis documentation. A good certificate lists the compounds actually measured, the method used, and the batch it applies to. In Australia, products sold as low-THC hemp-derived extracts sit in a complicated regulatory space, and the TGA's scheduling decisions hinge on the actual cannabinoid content of the final product, not the category name on the label.

Isolate: pure compound, known quantity

An isolate is a single purified cannabinoid, most commonly CBD, extracted and processed to remove all other plant material, including other cannabinoids, terpenes, flavonoids, and lipids. The resulting substance is typically a crystalline powder or fine white solid, analytically characterised at 98–99%+ purity. Because the purification is so thorough, the isolate is usually an ingredient that is later combined with a carrier, rather than a finished product in its own right.

From a pharmacokinetic standpoint, isolates offer something the other two categories can't: a known, singular compound for which dose-concentration relationships can be more precisely characterised. That's genuinely useful in research settings, where a single variable is easier to study than a mixture. A 2019 paper from researchers at the Hebrew University, the same team whose earlier work gave rise to much of the entourage effect literature, noted that isolate-based CBD produced a narrower dose-response window in rodent models compared to whole-plant extracts, which showed a broader, flatter curve. Whether that translates directly to human pharmacology is an open question, and I'd be careful about overstating that finding. Animal models are a starting point for hypotheses, not a verdict on people.

For pharmacokinetic purposes, isolate CBD still faces the same bioavailability constraints as other oral cannabinoids. Oral bioavailability of CBD is typically cited at 6–19% in the published literature, influenced heavily by first-pass metabolism in the liver and the compound's high lipophilicity (it dissolves in fats far better than in water). Formulation, whether oil-based, emulsified, or encapsulated, affects absorption more than the full-spectrum/isolate distinction does. Storage matters too, and shelf life and storage of cannabinoid products explains why.

The entourage effect: legitimate hypothesis, contested evidence

The term entourage effect was coined by Raphael Mechoulam and Shimon Ben-Shabat in a 1998 paper in the European Journal of Pharmacology, originally describing endogenous lipid interactions rather than whole-plant cannabis. It was later extended, fairly loosely, to the idea that phytocannabinoids and terpenes act in concert to produce effects that no single compound could achieve alone. That drift from the original meaning is worth remembering whenever the phrase appears in marketing copy.

The hypothesis has genuine scientific legs. Terpenes like beta-caryophyllene are known to interact directly with CB2 receptors. Linalool modulates GABAergic signalling. Myrcene has been studied for its interaction with multiple receptor types. These aren't speculative, there's in vitro and some in vivo literature behind each of those statements. Terpenes such as beta-pinene and alpha-pinene are studied in the same general context.

But "the entourage effect exists" and "therefore full-spectrum is better than isolate" is a logical jump the clinical literature hasn't reliably landed. The first statement is about mechanism; the second is about outcomes, and those need different kinds of evidence. The 2019 Hebrew University study mentioned above found evidence for the effect in that specific context. A 2020 Cochrane-style systematic review found the evidence base insufficient to draw population-level conclusions. The honest position is: plausible, under active investigation, not settled.

My own view is that the entourage literature is messier than either proponents or sceptics typically acknowledge. Enthusiasts lean on the mechanism studies and skip the missing clinical data, while dismissive commentators treat an unproven claim as a disproven one. Neither is a fair reading of the evidence.

How these categories interact with the Australian regulatory framework

The TGA's scheduling of cannabis-derived products under the Poisons Standard is based on the presence and concentration of specific cannabinoids, primarily THC and CBD, in the final formulation. The category name, full-spectrum, broad-spectrum, isolate, carries no independent legal weight in the scheduling decision. For the underlying definitions, the glossary entry on the Poisons Standard is a useful companion.

CBD in concentrations up to 150mg per pack and no more than 60mg per day was down-scheduled to Schedule 3 (pharmacist-only) in February 2021, opening a narrow pathway for over-the-counter access to low-dose CBD isolate products for adults aged 18 and over. Products containing THC, or CBD in higher concentrations, remain Schedule 4 or Schedule 8 and require a valid prescription. The glossary entry for Schedule 4 (prescription only) explains what that status means in practice. The TGA's Australian Register of Therapeutic Goods (ARTG) lists approved products; anything not on the ARTG and not accessed via SAS or Authorised Prescriber is, simply, not legally supplied. The legal logic behind that gap is set out in unapproved therapeutic goods: the legal basis, and medicinal cannabis product categories 1–5 shows how products are grouped.

Good manufacturing practice (GMP) compliance is required for any therapeutic goods supplied in Australia. This matters for the full-spectrum/isolate distinction because GMP standards require batch-to-batch consistency and documented analytical testing, the very thing that makes "full-spectrum" a harder specification to hold than "isolate." A single compound is simple to specify. A mixture of dozens of compounds, some of them volatile, is not.

The pharmacology underneath all three

Regardless of which category a product falls into, the cannabinoids in it interact primarily with the endocannabinoid system, a retrograde neuromodulatory network present throughout the central nervous system and periphery. CB1 receptors are densely expressed in the brain and spinal cord; CB2 receptors are more prominent in immune tissue. Endogenous ligands like anandamide use the same binding sites. A broader introduction is available in the endocannabinoid system in whole-body physiology.

THC is a partial agonist at both CB1 and CB2. CBD has a lower affinity for both receptors directly and appears to modulate the system through indirect mechanisms, including inhibition of fatty acid amide hydrolase (FAAH), the enzyme that breaks down anandamide. Minor cannabinoids like CBG interact with the system differently again; some act as partial agonists, some as antagonists or negative allosteric modulators. The full receptor pharmacology of many minor cannabinoids, CBDV, CBG, delta-8-THC, and others, is still being characterised in the literature.

Which is the honest answer to "which formulation type is best?" There isn't one, not at the level of current evidence, and certainly not independent of the specific cannabinoid concentrations, terpene profiles, and bioavailability of the actual product in question. Anyone who tells you otherwise is either ahead of the literature or, more likely, ahead of the evidence.

Sources

Tom Whitfield, Health librarian, references & fact-checking

Common questions

What is the difference between full-spectrum and broad-spectrum cannabis extracts?: Full-spectrum extracts retain the complete cannabinoid and terpene profile of the source plant, including THC. Broad-spectrum extracts have undergone a processing step to remove or reduce THC to non-detectable levels while aiming to preserve other cannabinoids and terpenes. Neither term has a standardised pharmacopoeial definition, so third-party certificate of analysis documentation is the only reliable way to verify actual content.
Is a CBD isolate more or less bioavailable than a full-spectrum extract?: Bioavailability is primarily determined by the formulation and delivery method — whether oil-based, emulsified, encapsulated, and so on — rather than by the full-spectrum versus isolate distinction itself. Oral bioavailability of CBD is typically cited at 6–19% in published literature regardless of extract type, largely due to first-pass metabolism and CBD's high lipophilicity.
Is full-spectrum cannabis available over the counter in Australia?: No. Products containing THC above a prescribed threshold are Schedule 8 controlled drugs or Schedule 4 prescription-only medicines under Australia's Poisons Standard and require access via the TGA's Special Access Scheme or an Authorised Prescriber. Only low-dose CBD products (up to 150mg per pack, max 60mg/day) were down-scheduled to Schedule 3 (pharmacist-only) in 2021 — and those are typically isolate or broad-spectrum formulations with non-detectable THC.
What is the entourage effect and is it scientifically accepted?: The entourage effect is a hypothesis proposing that cannabinoids and terpenes act together to produce effects that no single compound could achieve alone. There is credible mechanistic evidence supporting the plausibility of this hypothesis — terpenes like beta-caryophyllene interact directly with CB2 receptors, for instance — but clinical evidence sufficient to draw firm population-level conclusions has not yet been established. It is an active area of research, not a settled finding.
Does 'broad-spectrum' mean there is definitely zero THC in a product?: Not necessarily. 'Broad-spectrum' describes an intent — to remove THC while retaining other plant compounds — but the term has no single regulated definition across the industry. Analytical verification via a certificate of analysis from an accredited third-party laboratory is the only way to confirm actual THC content in a specific product batch.